Topische Therapie beim oberflächlichen Harnblasenkarzinom

Bahnson R, Brasman S, Greenberg R, Brown T, Dalkin B, Middleton R, Soloway MS, Steinberg G, Wajsman Z (1998) Multicenter efficiacy and safety study of intravesical AD 32 (Valrubicin) in the treatment of patients with refractory bladder carcinoma in situ. J Urol 159: 551 (A) Baniel J, Graus D, Engelstein D, Livne PM, Sella A (1998) Intravesical BCG treatment for primary T1 GIII TCC of the bladder. Eur Urol 33: 405 (A) Böhle A, Jocham D (1998) Die intravesikale Immuntherapie mit Bacillus Calmette Guérin-Fakten, Vergleich, Ergebnisse. Fischer, Stuttgart Jena Lübeck Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Boeken Kruger C, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of cancer randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short term versus longtermtratment. J Urol 153: 934–941 Bonfil RD, Russo DM, Schmilovich AJ, Garcia-Palazzo IB (1997) Intravesical therapy of vinorelbin tartrate: antitumor activity in orthotopic murine cell carcinoma of the bladder. J Urol 158: 912–915 Heike C, Wirth M (1999) An opinion poll of German urologists concerning the current treatment of pT1, GIII transitional cell carcinoma of the bladder. Eur Urol 35: 91 (A) Herr MW (1997) Tumor progression and survival in patients with pT1, GIII bladder tumours: 15 year outcome. Br J Urol 80: 762–765 Lamm DL, Blumenstein B, Sarosdy M, Grossmann B, Crawford D (1997) Significant long-term patient benefit with BCG maintenance therapy: a southwest oncology group study. J Urology 157: 831 (A) Malmström P-U, Wijkström H, Lundholm C, Wester K, Cusch C, Norlen BJ (1999) 5-year followup of a randomized prospective study comparing Mitomycin C and Bacillus Calmette-Guérin in patients with superficial bladder carcinoma. J Urol 161: 1124–1127 Martinez-Pinero JA, Flores N, Isorna S (1999) Comparison between a standard BCG does (81 mg) versus a three fold reduced dose (27 mg) in superficial bladder cancer. Final analysis of CUETO 90 008 prostpective study. Eur Urol 35: 153 (A) Morales A, Chin JL (1997) Mycobacterial cell wall (MCW) as an alternative to BCG in the treatment of Carcinoma in situ (CIS) of the bladder: an efficiacy study. J Urol 157: 834 (A) Ofer N, Halachmi S, Madjar M, Issaq E, Moskovitz B, Dalai E,Aronson M (1999) The antineoplastic activity of gemcitabine on experimental superficial bladder cancer. Eur Urol 35: 99 (A) Den Otter W, Dobrowolski Z, Bugajski A, Papla B, van der Mejden APM, Koten JW, Boon TA, Siedlar M, Zembela M (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesions in 8 of 10 patients. J Urol 159: 1183–1186 Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN (1995) Bacillus Calmette-Guérin in the treatment of pT1, G III transitional cell carcinoma of the bladder: long term results. J Urol 154: 2054–2058 (A) Rübben H, Otto T (1997) Harnblasenkarzinom. In: Rübben H (Hrsg) Uroonkologie. Springer, Berlin Heidelberg New York, S 85–167 Vegt PD, van der Mejden AP, Sylvester R, Brausi M, Holtl W, de Balincourt C (1997) Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30 911. J Urol 157: 1246–1249 Vincenzo S, Ercole G, Vaccarella Pavone C, Pavone MM (1999) Adjuvant intravesical combination of Epirubicin and Mitomycin in T1 GIII transitional cell carcinoma of the bladder. Eur Urol 35: 94 Witjes JA, v. d. Mejden APM, Colette L, Sylvester R, Debruyne FMJ, v. Aubel A, Witjes WPM (1998) Long term follow-up of an EORTC randomized prospective trial comparing intravesical Bacille Calmette Guèrin-RIVM and Mitomycin C in superficial bladder cancer. Urology 52: 403–410 Witjes WPJ, Hall RR, Schulman CC, Zurlo M, Fittipaldo A, Riggi M, Debruyne F (1999) Bropirimin vs. BCG in BCG naive patients with carcinoma in situ of the urinary bladder. Results of a european randomized phase III trial. Eur Urol 33: 407 (A) Zlotta AR, Drowart A, Van Vooren L-P, Simon J, Schulman CC, Huygen K (1998) What is the optimal schedule for intravesical BCG therapy: are six instillations necessary? Eur Urol 33: 402 (A)